Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Burroni

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski, et al.
The American Journal of Surgical Pathology|December 13, 2018
Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSAClémentine Sarkozy, Christiane Copie-Bergman, Diane Damotte, et al.
British Journal of Haematology|November 12, 2019
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progressionLaurane Cottin, Jérémie Riou, Corentin Orvain, et al.
The Lancet. Haematology|September 24, 2020
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA groupSteven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, et al.
Leukemia|September 15, 2025
Molecular profiling and risk stratification in solitary bone plasmacytomaBarbara Burroni, Stéphanie Harel, Raphaele Seror, et al.
Gastroenterology|April 19, 2026
CLONAL LYMPHOCYTE EXPANSIONS AND JAK-STAT PATHWAY MUTATIONS DEFINE A PATHOGENIC CONTINUUM DRIVING RESISTANCE TO GLUTEN-FREE DIET IN CELIAC DISEASEGeorgia Malamut, Nicolas Guégan, Francesco Carbone, et al.
Haematologica|December 30, 2021
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort studyAmira Marouf, Anne Segolene Cottereau, Salim Kanoun, et al.
Medicina (Kaunas, Lithuania)|March 26, 2022
Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of LiteratureMargot Denier, Sarah Tick, Romain Dubois, et al.
Blood Cancer Journal|April 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyClémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Nature Communications|January 30, 2024
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulationOlivier Kosmider, Céline Possémé, Marie Templé, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski, et al.
The American Journal of Surgical Pathology|December 13, 2018
Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSAClémentine Sarkozy, Christiane Copie-Bergman, Diane Damotte, et al.
British Journal of Haematology|November 12, 2019
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progressionLaurane Cottin, Jérémie Riou, Corentin Orvain, et al.
The Lancet. Haematology|September 24, 2020
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA groupSteven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, et al.
Leukemia|September 15, 2025
Molecular profiling and risk stratification in solitary bone plasmacytomaBarbara Burroni, Stéphanie Harel, Raphaele Seror, et al.
Gastroenterology|April 19, 2026
CLONAL LYMPHOCYTE EXPANSIONS AND JAK-STAT PATHWAY MUTATIONS DEFINE A PATHOGENIC CONTINUUM DRIVING RESISTANCE TO GLUTEN-FREE DIET IN CELIAC DISEASEGeorgia Malamut, Nicolas Guégan, Francesco Carbone, et al.
Haematologica|December 30, 2021
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort studyAmira Marouf, Anne Segolene Cottereau, Salim Kanoun, et al.
Medicina (Kaunas, Lithuania)|March 26, 2022
Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of LiteratureMargot Denier, Sarah Tick, Romain Dubois, et al.
Blood Cancer Journal|April 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyClémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Nature Communications|January 30, 2024
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulationOlivier Kosmider, Céline Possémé, Marie Templé, et al.
Pageof 6